Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers for the Treatment of Hypertension in Adults With Type 2 Diabetes: Why We Favour Angiotensin Receptor Blockers.

[1]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[2]  M. Nieuwdorp,et al.  SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[3]  M. Jardine,et al.  Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. , 2017, Journal of the American Society of Nephrology : JASN.

[4]  A. Ades,et al.  Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes-Network meta-analysis of randomized trials. , 2016, Journal of diabetes and its complications.

[5]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[6]  Akshay S. Desai,et al.  Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. , 2016, The lancet. Diabetes & endocrinology.

[7]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[8]  Xuelin He,et al.  Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. , 2014, JAMA internal medicine.

[9]  T. Mavrakanas,et al.  Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. , 2014, European journal of internal medicine.

[10]  P. Peduzzi,et al.  Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.

[11]  A. Esteghamati,et al.  Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  J. Craig,et al.  Antihypertensive agents for preventing diabetic kidney disease. , 2012, The Cochrane database of systematic reviews.

[13]  Nish Chaturvedi,et al.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[14]  E. Schiffrin,et al.  What Is the Ideal Blood Pressure Goal for Patients with Diabetes Mellitus and Nephropathy? , 2012, Current Cardiology Reports.

[15]  K. Matsushita,et al.  Comparison Between Valsartan and Amlodipine Regarding Cardiovascular Morbidity and Mortality in Hypertensive Patients With Glucose Intolerance: NAGOYA HEART Study , 2012, Hypertension.

[16]  J. Chan,et al.  Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study , 2011, Diabetologia.

[17]  T. Ogihara,et al.  Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial , 2010, Hypertension Research.

[18]  Lars E. Rydn,et al.  Effect of Telmisartan on Renal Outcomes , 2009, Annals of Internal Medicine.

[19]  S. Yusuf,et al.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial , 2008, The Lancet.

[20]  S. Yusuf,et al.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.

[21]  W. Ahmad.  Effect of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial: The Telmisartan Randomised Assessment Study in ACE intolerant subjects with cardiovascular Disease (TRANSCEND) , 2008 .

[22]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[23]  J. Mustonen,et al.  Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. , 2004, The New England journal of medicine.

[24]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[25]  M. Pfeffer,et al.  Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy , 2003, Annals of Internal Medicine.

[26]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[27]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[28]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[29]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[30]  S. Ross,et al.  Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. , 2000, Kidney international.

[31]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[32]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .